ABVX News

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax Announces Launch of Public Offering of American Depositary Shares

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Abivax S.A. (ABVX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Abivax S.A. (ABVX) and Encourages Shareholders to Learn More About the Investigation

ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

Abivax S.A. (ABVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation